key: cord-0989294-a0ig9kie authors: Li, Cesheng; Yu, Ding; Wu, Xiao; Liang, Hong; Zhou, Zhijun; Xie, Yong; Li, Taojing; Wu, Junzheng; Lu, Fengping; Feng, Lu; Mao, Min; Lin, Lianzhen; Guo, Huanhuan; Yue, Shenglan; Wang, Feifei; Peng, Yan; Hu, Yong; Wang, Zejun; Yu, Jianhong; Zhang, Yong; Lu, Jia; Ning, Haoran; Yang, Huichuan; Fu, Daoxing; He, Yanlin; Zhou, Dongbo; Du, Tao; Duan, Kai; Dong, Demei; Deng, Kun; Zou, Xia; Zhang, Ya; Zhou, Rong; Gao, Yang; Zhang, Xinxin; Yang, Xiaoming title: Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan date: 2021-06-03 journal: bioRxiv DOI: 10.1101/2021.04.05.437224 sha: d5c0dfcafa6cfe1a74937b671babd5a01d8c8136 doc_id: 989294 cord_uid: a0ig9kie To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 64.3% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development. Several SARS-CoV-2 vaccines have been approved worldwide, but their longevity 44 of immune protection is still uncertain. Evaluating the durability of the immune 45 response, especially humoral immune response, induced by SARS-CoV-2 is essential 46 to understand the pathogenesis of SARS-CoV-2 and predict the longevity of its vaccine 47 7 as moderate titers, and 1:1280 and ≥ 1:2560 as high titers 13 . As shown in Figure 1B , 118 the proportion of higher titers displays a time-dependent downward trend, while the 119 proportion of negative titers shows the opposite. Specifically, the proportions of plasma 120 samples with moderate and high titers of RBD-IgG are 72.6%, 41.3%, and 27.2% at the 121 early, middle, and late stages following diagnosis, respectively (Supplementary Table 122 1). It should be noted that even at the early stage following diagnosis, the titers of RBD-123 IgG in 5.4% of the convalescent plasma donors are at an level (<1:80) (Supplementary 124 Table 1 ), which might be attributed to the failure of antibody production during 125 infection or the low sensitivity of the method for antibody detection. As expected, at 126 the late stage following diagnosis, the proportion of negative titers is increased to 18.8% 127 (Supplementary Table 1) . 128 129 Longitudinal analysis of RBD-IgG responses. We further determine the kinetics of 130 RBD-IgG in COVID-19 plasma donors within 12 months after diagnosis. Monthly 131 RBD-IgG titers are calculated and shown as geometric mean titers (GMT). As displayed 132 in Figure 2A , the RBD-IgG titers in convalescent plasma donors decrease within 12 133 months. After 9 months, the RBD-IgG titers begin to stabilize at a GMT of 134 approximately 200. The RBD-IgG titer at the 12th month (a GMT of 189) following 135 diagnosis is 69.9% lower than that at the 1st month (a GMT of 628) following diagnosis 136 ( Figure 2A ). As aforementioned, the antibody response dramatically augments at the 137 initial stage after SARS-CoV-2 infection, followed by gradual declining 1, 10, 11 . Since 138 8 the plasma samples are collected after the discharge of the plasma donors from hospital 139 (no less than 3 weeks after symptom onset), the period of antibody generation and 140 expansion during the initial stage of onset might not be included. 141 In addition, we further analyze the kinetics of RBD-IgG in 14 COVID-19 142 convalescent plasma donors who repeatedly donate plasma for 3 or more than 3 times. 143 Consistent with the general kinetics of RBD-IgG for COVID-19 convalescent plasma 144 donors, the titers of individual plasma clearly display a downward trend within 145 approximately 300 days ( Figure 2B ). 146 In order to evaluate the stability of RBD-IgG titers in COVID-19 convalescent 147 plasma donors after a long period of time, we re-collect the plasma from 237 donors, 148 who present different titer levels of RBD-IgG at the early stage following diagnosis, 149 during the 10th and 11th months after diagnosis. It shows that the plasma donors with 150 higher initial titers remained faster RBD-IgG attenuation ( Figure 3A ). Interestingly, 151 after a long period of time, the RBD-IgG titers of the plasma donors with higher initial 152 titers are still higher than those with lower initial titers. From the 1st-2nd month to the 153 10th-11th month, the RBD-IgG titer is decreased by 71.4% to an GMT of 207 in the 154 237 plasma donors ( Figure 3A ). Additionally, we analyze the changes of RBD-IgG 155 titers in plasma donors stratified by the initial titers from the early stage to the 10th and 156 11th months. As shown in Figure 3B According to our findings, the RBD-IgG response in more than 70% COVID-19 232 convalescent plasma donors can persist for at least 12 months, indicating that 233 vaccination can effectively restrict the spread of SARS-CoV-2. We will also examine 234 the changes of RBD-IgG titers over a longer period of time. Compared with the titer 235 obtained at the 1st month, the RBD-IgG titer is decrease by 69.9% at the 12th month. 236 13 Moreover, the proportion of the plasma donors whose RBD-IgG titers remained at or 237 above the moderate titer at the late stage following diagnosis is 27.2% (Supplementary 238 Table 1 ). 239 Furthermore, we find that although the RBD-IgG titer gradually decreases over We also evaluate the stability of RBD-IgG with different titers (stratification is 248 based on the titer value at the early stage following diagnosis) after a long time period 249 (the 10th and 11th months). Although more rapid attenuation of RBD-IgG is observed 250 in the plasma donors with high titers, after a long time period, the RBD-IgG in plasma 251 donors with higher initial titers remains to be higher than those with lower initial titers. 252 Interestingly, we find that the RBD-IgG titers significantly increase in 11.67% of the 253 low-titer population and 1.87% of the moderate-titer population during the 10th-11th history of blood-borne diseases, and screened by clinicians following blood donation 301 standards. The interval between two plasma collections was no less than 14 days. 302 As shown in Figure 6A are categorized as 1:80 (the actual value range is greater than or equal to 80 but less 510 than 160), 1:160 (the actual value range is greater than or equal to 160 but less than 511 320), 1:320 (the actual value range is greater than or equal to 320 but less than 640), 512 1:640 (the actual value range is greater than or equal to 640 but less than 1280), 1:1280 513 (the actual value range is greater than or equal to 1280 but less than 2560) and 1:2560 514 (the actual value range is greater than or equal to 2560). Titers less than 1:80 are 515 considered as negative. SARS-CoV-2 immunity: review 398 and applications to phase 3 vaccine candidates Duration of antibody responses after severe acute respiratory 401 syndrome Pathogenesis and transmission of SARS-CoV-2 in golden 404 hamsters Tissue 407 distribution of ACE2 protein, the functional receptor for SARS coronavirus. A 408 first step in understanding SARS pathogenesis Characterization of spike glycoprotein of SARS-CoV-2 on virus 411 entry and its immune cross-reactivity with SARS-CoV Relationship between anti-spike protein antibody titers and 415 SARS-CoV-2 in vitro virus neutralization in convalescent plasma. bioRxiv Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing 419 Human Angiotensin-Converting Enzyme 2 Effectiveness of convalescent plasma therapy in severe COVID-422 19 patients IgA-Ab response to spike glycoprotein of SARS-CoV-2 in 425 patients with COVID-19: A longitudinal study Immunological memory to SARS-CoV-2 assessed for up to 8 429 months after infection Antibody testing for COVID-19: A report from the National 432 COVID Scientific Advisory Panel The prevalence of antibodies to SARS-CoV-2 among blood 435 donors in China Robust neutralizing antibodies to SARS-CoV-2 infection 438 persist for months SARS-CoV-2 proteome microarray for global profiling of 441 COVID-19 specific IgG and IgM responses Convergent antibody responses to SARS-CoV-2 in 444 convalescent individuals Relationship between the ABO Blood Group and the COVID-19 Effect of an inactivated vaccine against SARS-CoV-2 on safety and 450 immunogenicity outcomes: Interim analysis of 2 randomized clinical trials Antibodies and B cell memory in viral immunity Primary exposure to SARS-CoV-2 protects against reinfection in 457 rhesus macaques COVID-19 herd immunity: where are we Immunological considerations for COVID-19 vaccine strategies Dynamics of neutralizing antibody titers in the months 467 after SARS-CoV-2 infection Seroprevalence of anti-SARS-CoV-2 antibodies in 470 COVID-19 patients and healthy volunteers up to 6 months post disease onset 6-month consequences of COVID-19 in patients discharged 474 from hospital: a cohort study SARS-CoV-2 infection induces sustained humoral immune 477 responses in convalescent patients following symptomatic COVID-19 Kinetics of Anti-SARS-CoV-2 IgG Antibodies in Hemodialysis 481 Patients Six Months after Infection Seroprevalence and humoral immune durability of anti-SARS-CoV-484 2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional 485 study Neutralizing antibody responses to SARS-CoV-2 in 488 symptomatic COVID-19 is persistent and critical for survival Extending human IgG half-life using structure-guided design SARS-CoV-2 infection induces long-lived bone marrow 495 plasma cells in humans Humoral response and PCR positivity in patients with 498 USA: an observational study We thank all the plasma donors for participating in this study. This Plasma collection was carried out at least 3 weeks after the first symptom onset of 312 patients. Beijing, China) was used to test the titer of RBD-IgG. COVID-19 convalescent plasma. 317 (assigned as 1:320, lot number: 2020021702, prepared by Sinopharm Wuhan Plasma-318 derived Biotherapies Co., Ltd.) was used as the reference standard. The target titer was 319 obtained from 10 tests with Wantai SARS-CoV-2 IgG kit, which was expressed as the 320 dilution and was defined by the largest dilution that optical density (OD) value is higher 321 than cut-off value of the kit. After validation of linearity, range, precision, the 322 quantitative mothed was used to test samples. The reference standard 2-fold serially 323 diluted with Wantai kit specimen dilution buffer at 6 concentrations (1:10, 1:20, 1:40, Statistical analyses. GraphPad Prism 9.0 was used for statistical analysis. As for GMT 358 calculation, the value of RBD-IgG titer that was lower than the range (<1:10) was set 359 to 1. The influences of gender and blood type on RBD-IgG titer were analyzed by two-360 way ANOVA for inter-group difference, and by a two-tailed nonparametric Mann-361 Whitney t-test for median difference between groups. Unpaired t-test with Welch's 362 correction was adopted for further analysis when significant mean difference was found 363 between genders. Two-tailed pearson correlation test was used to examine the 364 association between age and RBD-IgG titers. Neutralizing antibody titers were Log4-365 transformed ,RBD-IgG titers were Log2-transformed, and linear regression analysis and 366Spearman's correlation were used to examine the association between neutralizing 367 antibody titers and RBD-IgG titers. A P-value less than 0.05 was considered significant. 368 369 Data Availability Statement: The authors declare that the data supporting the findings 370 of this study are available within the paper and its supplementary and Source files. 371 20 Other data that support the findings of this study are available from the corresponding 372 author upon reasonable request. 373 374 375 21